ResearchMoz

U.S. Vaccine Market - U.S. Industry Analysis, Size, Share, Growth, And Forecast, 2012 - 2018

Transparency Market Research
Published Date » 2012-09-17
No. Of Pages » 71
   
 This report helps to identify factors, which will be the driving force behind the U.S. vaccine market and sub-markets in the next six years. The report provides extensive analysis of the US vaccine industry, current market trends, industry drivers and challenges for better understanding of the U.S.vaccine market structure. The report has segregated the U.S. vaccine industry in terms of product type. Annual estimates and forecasts are provided for the period 2012 through 2018 in terms of in USD million. 
   
  The report helps in providing a comprehensive overview for  
 
 
 Market forces that are driving and restraining the growth of the industry 
 Opportunities for the application segments  
 Up-to-date analysis of the latest trends in the industry  
 Acumen...
TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 METHODOLOGY

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 U.S. VACCINE MARKET, 2012 - 2018
3.1 MARKET OVERVIEW
3.2 VACCINE MARKET CHARACTERISTICS
3.3 LAWS AND REGULATIONS
3.3.1 VACCINE APPROVAL PROCESS
3.4 U.S. VACCINE MARKET ESTIMATE AND FORECAST, 2012 - 2018
3.4.1 MARKET SHARE BY VACCINE TYPE
3.5 LIST OF COMPANIES SUPPLYING VACCINES IN THE U.S.
3.6 VACCINE PRICING
3.6.1 PRICES FOR VACCINES CONTAINING THIMEROSAL AS A PRESERVATIVE
3.6.2 PRICES OF VACCINES FREE OF PRESERVATIVES:
3.7 MARKET DYNAMICS
3.7.1 DRIVERS
3.7.1.1 Rise in incidences of viral infection driving the growth of vaccine market in the U.S.
3.7.1.2 Biotechnology research enabling synthesis of new vaccines to target complex human diseases driving the vaccine market
3.7.1.3 Government recommendation for adult and adolescent immunization will boost the growth of Vaccine market in U.S.
3.7.1.4 Rise in infectious diseases in animals driving the market
3.7.2 RESTRAINTS
3.7.2.1 Cost of refrigeration
3.7.2.2 Short functional shelf life of certain vaccines will have negative impact on the market growth
3.7.3 OPPORTUNITIES
3.7.3.1 Huge product pipeline of the multinational firms will act as an opportunity for future growth
3.8 IMPACT ANALYSIS OF DRIVERS
3.9 IMPACT ANALYSIS OF RESTRAINTS
3.10 PORTER’S FIVE FORCE ANALYSIS
3.10.1 BARGAINING POWER OF SUPPLIER
3.10.2 BARGAINING POWER OF BUYER
3.10.3 RIVALRY AMONG EXISTING COMPETITORS
3.10.4 THREAT OF NEW ENTRANTS
3.10.5 THREAT OF SUBSTITUTE

CHAPTER 4 U.S. VACCINE MARKET BY PRODUCT TYPE
4.1 HUMAN VACCINE
4.1.1 MARKET ANALYSIS, SIZE AND FORECAST
4.1.2 MARKET ATTRACTIVENESS ANALYSIS FOR HUMAN VACCINE MARKET
4.1.3 PEDIATRIC VACCINES
4.1.3.1 Market Analysis, Size and Forecast
4.1.3.2 Pediatric vaccine price list
4.1.3.3 Pediatric Influenza Vaccine price list
4.1.3.4 HaemophilusInfluenzae Type B
4.1.3.4.1 Hib Pricing
4.1.3.5 Hepatitis A
4.1.3.5.1 HAV Pricing
4.1.3.6 Hepatitis B
4.1.3.6.1 Hepatitis B Pricing
4.1.4 ADULT & ADOLESCENT VACCINES
4.1.4.1 Market Analysis, Size and Forecast
4.1.4.2 Adult vaccine price list
4.1.4.3 Adult Influenza Vaccine price list
4.1.5 OTHER HUMAN VACCINES
4.1.5.1 Market Analysis, Size and Forecast
4.2 ANIMAL VACCINE
4.2.1 MARKET ANALYSIS, SIZE AND FORECAST
4.2.2 MARKET ATTRACTIVENESS ANALYSIS FOR ANIMAL VACCINE
4.2.3 LIVESTOCK VACCINES
4.2.3.1 Market Analysis, Size and Forecast
4.2.3.2 Bovine Vaccines
4.2.3.2.1 Market Analysis, Size and Forecast
4.2.3.3 Porcine Vaccines
4.2.3.3.1 Market Analysis, Size and Forecast
4.2.3.4 Ovine Vaccines
4.2.3.4.1 Market Analysis, Size and Forecast
4.2.4 COMPANION ANIMAL VACCINES
4.2.4.1 Market Analysis, Size and Forecast
4.2.4.2 Feline Vaccines
4.2.4.2.1 Market Analysis, Size and Forecast
4.2.4.3 Canine Vaccines
4.2.4.3.1 Market Analysis, Size and Forecast
4.2.4.4 Equine Vaccines
4.2.4.4.1 Market Analysis, Size and Forecast
4.2.5 OTHER ANIMAL VACCINES
4.2.5.1 Market Analysis, Size and Forecast

CHAPTER 5 COMPETITIVE LANDSCAPE
5.1 MARKET SHARE ANALYSIS
5.2 COMPETITIVE ANALYSIS FOR KEY MARKET PLAYERS

CHAPTER 6 COMPANY PROFILE
6.1 SANOFI-AVENTIS
6.1.1 COMPANY OVERVIEW
6.1.2 FINANCIAL OVERVIEW
6.1.3 SWOT ANALYSIS
6.1.1 RECENT DEVELOPMENT
6.2 GLAXOSMITHKLINE
6.2.1 COMPANY OVERVIEW
6.2.2 FINANCIAL OVERVIEW:
6.2.3 SEGMENT OVERVIEW
6.2.4 SWOT ANALYSIS
6.2.5 RECENT DEVELOPMENTS
6.3 MERCK & COMPANY INCORPORATED
6.3.1 COMPANY OVERVIEW
6.3.2 FINANCIAL OVERVIEW:
6.3.1 RECENT DEVELOPMENT
6.4 PFIZER INCORPORATED
6.4.1 COMPANY OVERVIEW
6.4.2 FINANCIAL OVERVIEW
6.4.3 RECENT DEVELOPMENT
6.5 ASTRAZENECA PLC
6.5.1 COMPANY OVERVIEW
6.5.2 FINANCIAL OVERVIEW:
6.5.3 RECENT DEVELOPMENT
6.6 NOVARTIS AG
6.6.1 COMPANY OVERVIEW
6.6.2 FINANCIAL OVERVIEW:
6.6.3 SWOT ANALYSIS
6.6.1 RECENT DEVELOPMENT
6.7 BOEHRINGER
6.7.1 COMPANY OVERVIEW
6.7.2 NET SALES BY BUSINESS
6.7.3 SWOT ANALYSIS
6.7.4 RECENT DEVELOPMENT

List of Tables


TABLE 1 ACTS AND REGULATIONS PERTINENT TO VACCINE DEVELOPMENT 
TABLE 2 SELECT FDA AND ICH GUIDANCE DOCUMENTS RELEVANT TO VACCINE DEVELOPMENT 
TABLE 3 LOT-RELEASE TESTING GUIDLINES 
TABLE 1 U.S. VACCINE MARKET REVENUE, BY PRODUCT TYPE, 2012 - 2018, (USD MILLION) 
TABLE 2 GSK PRODUCT PIPELINE 
TABLE 3 U.S. HUMAN VACCINE MARKET REVENUE, BY PRODUCT TYPE 2012 - 2018 (USD MILLION) 
TABLE 4 U.S. ANIMAL VACCINE MARKET REVENUE, BY PRODUCT TYPE 2012 - 2018 (USD MILLION) 
TABLE 5 U.S. LIVESTOCK VACCINES MARKET REVENUE, BY PRODUCT TYPE 2012 - 2018 (USD MILLION) 
TABLE 6 U.S. COMPANION ANIMAL VACCINES MARKET REVENUE, BY PRODUCT TYPE 2012- 2018 (USD MILLION) 

List of Figures


FIG. 1 U.S. VACCINE MARKET REVENUE, BY PRODUCT TYPE, 2012 - 2018, (USD MILLION) 
FIG. 2 FDA REGULATORY REVIEW PROCESS 
FIG. 3 VACCINE APPROVAL PROCESS 
FIG. 4 U.S. VACCINE MARKET REVENUE, 2010 - 2018 (USD MILLION) 
FIG. 5 U.S. VACCINE MARKET SHARE, BY VACCINE TYPE 2012 ESTIMATE (%) 
FIG. 6 IMPACT ANALYSIS OF DRIVERS 
FIG. 7 PORTER’S FIVE FORCE ANALYSIS FOR U.S. VACCINE MARKET 
FIG. 8 U.S. HUMAN VACCINE MARKET REVENUE2010 - 2018(USD MILLION) 
FIG. 9 MARKET ATTRACTIVENESS ANALYSIS FOR U.S. HUMAN VACCINE MARKET 
FIG. 10 PEDIATRIC VACCINES MARKET REVENUE 2010 – 2018 (USD MILLION) 
FIG. 11 ADULT & ADOLESCENT VACCINESMARKETREVENUE 2010 - 2018(USD MILLION) 
FIG. 12 OTHER HUMAN VACCINESMARKETREVENUE2010 - 2018(USD MILLION) 
FIG. 13 U.S. ANIMAL VACCINEMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 14 MARKET ATTRACTIVENESS FOR U.S. ANIMAL VACCINE MARKET2012 
FIG. 15 LIVESTOCK VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 16 BOVINE VACCINES MARKETREVENUE 2010 - 2018 (USD MILLION) 
FIG. 17 PORCINE VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 18 OVINE VACCINES MARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 19 COMPANION ANIMAL VACCINESMARKETREVENUE2010 - 2018 (USD MILLION), 
FIG. 20 FELINE VACCINESMARKETREVENUE2010-2018 (USD MILLION) 
FIG. 21 CANINE VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 22 EQUINE VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 23 OTHER ANIMAL VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 24 MARKET SHARE OF MAJOR HUMAN VACCINE PRODUCERS IN THE U.S., 2011 (%) 
FIG. 25 MARKET SHARE OF MAJOR ANIMAL VACCINE PRODUCERS IN THE U.S., 2011 (%) 
FIG. 26 GLOBAL VACCINE PLAYERS SALES GROWTH 2012-2018 
FIG. 27 SANOFI-AVENTIS, PERFORMANCE CHART (2009-2011) 
FIG. 28 SANOFI-AVENTIS, SWOT ANALYSIS 
FIG. 29 GLAXOSMITHKLINE PLC AG, PERFORMANCE CHART (2006-2010) 
FIG. 30 GLAXOSMITHKLINE PLC AG, MARKET SHARE BY SEGMENT IN 2011 
FIG. 31 GLAXOSMITHKLINE PLC AG, SWOT ANALYSIS 
FIG. 32 MERCK & CO. , PERFORMANCE CHART (2007-2011) 
FIG. 33 MERCK, SWOT ANALYSIS 
FIG. 34 MERCK & CO. , PERFORMANCE CHART (2007-2011) 
FIG. 35 ASTRAZENECA PLC, MARKET SHARE BY SEGMENT IN 2011 
FIG. 36 ASTRAZENECA PLC, SWOT ANALYSIS 
FIG. 37 NOVARTIS AG, PERFORMANCE CHART (2007-2011) 
FIG. 38 NOVARTIS AG, SWOT ANALYSIS 
FIG. 39 BOEHRINGER, SWOT ANALYSIS 

Upcoming Reports:

Poland: hard coal market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the hard coal market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the hard coal market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main...
Poland: liver sausages market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the liver sausages market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the liver sausages market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of...
Cardiac Ablation Devices Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
By - Transparency Market Research
Ablation is a procedure that involves removal of surface with the help of chemical or laser. Cardiac ablation involves ablation of cardiac tissues, and is a minimally invasive procedure done with the help of a bundle of catheters. The procedure depends upon physical condition and malaise faced by the patient. Cardiac ablation is used to treat conditions of cardiac arrhythmias, viz. tachycardia (supraventricular/atrial), atrial fibrillation (paroxysmal/intermittent), atrial flutter and WPW (Wolff-Parkinson-White) syndrome. Cardiac arrhythmia and similar disorders arise as a result of...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Philippines Falsifies Chinese Accusation on Disputed Spartly Islands
May 5, 2015  
Philippines authorities challenged China for accusations pertaining to construction on the disputed Spartly Islands.  The official Colomo Jr, responded to accusations by spokesperson of Foreign Ministry at China Hua Chunying that Philippines was building defense and civilian facilities such as ports, airports, and barracks on Spratly Islands that are claimed as Nansha Islands by...
Apple Hires New Contractor for Spaceship Campus
May 5, 2015  
Apple has aroused speculation about the completion of its ‘spaceship’ campus at Cupertino by 2016. This has happened on account of hiring a new general contractor for the construction of Apple Campus 2. The new contractor in picture is Rudolph & Sletten Inc. which is a Silicon Valley company. The company will carry out the build out of the interior of Apple Campus 2...
WuXi Starts Work on Largest Biologics Pant in China
May 5, 2015  
WuXi Biologics announced that it has commenced construction on the US$150 million production facility which will be part of its biologics unit. The company further announced, the facility will be the largest in size biologics production facility in China. It will be the largest plant in the world for the product of mammalian type cell cultures that will employ disposable...
Deputy Chief of Shanghai-Listed Bank under Investigation
May 5, 2015  
The Chinese finance industry has been hit by another corruption probe with the deputy chief of Hua Xia Bank being investigated for suspected disciplinary violations. The mid-sized Chinese bank announced that the antigraft authorities are investigating the charges against Wang Yaoting, one of its four vice presidents. The lender is listed on Shanghai Stock Exchange. In its filing, the bank...
Three Public Sector Banks Seek Exemption from Payment of Dividend
May 5, 2015  
Out of the 24 listed public sector banks in India, Bank of India, Allahabad bank, and Union Bank of India has sought exemption from the payment of dividend, owing to the high provisioning for the non-performing assets. Based on credit growth, market valuation, performance of the bank, and available capital, the government has recently approved of diluting the equity share holding of 52...